Pricing Log in Create free account
Saturday 17 October 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bio-Techne Corp (TECH) P/S ratio

Alert me on P/S ratio

As of 16 October 2026, Bio-Techne Corp (TECH) trades at a P/S ratio of 9.3×. Over the past ten years it has ranged from 5.6× (May 2026) to 22.4× (September 2021); the current reading is higher than 48% of that period. That is in line with the Biotechnology industry median of 9.7× and above the Healthcare sector median of 3.4×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2026 9.1× 36.47%
FY2025 6.6× (31.80%)
FY2024 9.7× (13.68%)
FY2023 11.3× (8.20%)
FY2022 12.3× (34.38%)
FY2021 18.7× 37.22%
FY2020 13.7× 23.32%
FY2019 11.1× 28.17%
FY2018 8.6× 10.93%
FY2017 7.8× (7.33%)

Quarterly newest first

Period P/S ratio Change
Jun 2026 9.1× 34.41%
Mar 2026 6.7× (10.51%)
Dec 2025 7.5× 6.07%
Sep 2025 7.1× 6.97%
42 more quarters

Against its own ten years

Low 5.6× High 22.4×
Ten-year median 9.6×
Current reading's percentile 43

P/S ratio against peers

Company P/S ratio
PCVX Vaxcyte, Inc. compare n/m
BMRN BioMarin Pharmaceutical Inc. compare 3.1×
TECH Bio-Techne Corp 9.3×
MDGL Madrigal Pharmaceuticals, Inc. compare 10.2×
CORT Corcept Therapeutics Incorporated compare 14.0×
BBIO BridgeBio Pharma, Inc. compare 18.2×
KRYS Krystal Biotech, Inc. compare 21.2×
IBRX ImmunityBio, Inc. compare 58.1×
SMMT Summit Therapeutics PLC compare 16,149×
Biotechnology industry median 9.7×
Healthcare sector median 3.4×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on TECH